New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024 07:30 ET | Biogen Inc.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement...
Neurological Biomarkers Market Worth $14.45 Billion by 2027 – Comprehensive Report by The Insight Partners
October 30, 2023 07:32 ET | The Insight Partners
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Biomarkers are the molecules that indicate the presence of a disease. The biomarkers of the neurological disorders were not that accessible in earlier...
Newborn Screening Market Worth $2.48 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
October 09, 2023 08:45 ET | The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Newborn screening involves testing a newborn for serious medical conditions and certain harmful or potentially fatal disorders that are not apparent at...
Camelot Portfolios Announces Cash Alternatives and Hedging Strategies
March 30, 2023 15:19 ET | Camelot Portfolios LLC
MAUMEE, Ohio, March 30, 2023 (GLOBE NEWSWIRE) -- Camelot Portfolios today announces an expanded lineup of cash alternatives and hedging strategies to help Investment Advisors serve clients seeking...
Robotic Legs Will Help Children Walk for the First Time at Toronto Area Facility
July 12, 2022 14:00 ET | Trexo Robotics
TORONTO, July 12, 2022 (GLOBE NEWSWIRE) -- Thanks to an outpouring of community support, Kayla’s Children Centre won Trexo Robotics’ Canada- wide Trexo Plus Robotic Gait Trainer Giveaway.   ...
Enhanced Profiles Drive Firms to The Wealth Advisor's New Model Portfolio Selection Guide
Enhanced Profiles Drive BlackRock, Invesco and Boutique Managers to The Wealth Advisor's New Model Portfolio Selection Guide
October 22, 2021 14:03 ET | The Wealth Advisor
SANTA MONICA, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- The Wealth Advisor, a Marina Media LLC publication, today announced the upcoming launch of the first Model Portfolio & SMA Strategists:...
Biogen Responds to C
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
March 01, 2019 20:18 ET | Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...
La réaction de Bioge
La réaction de Biogen aux recommandations mises à jour de l’ACMTS concernant l’accès à SPINRAZA
March 01, 2019 20:18 ET | Biogen Canada
·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...
Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients
December 20, 2018 12:19 ET | Biogen Canada
The decision follows positive recommendation from the Institut national d'excellence en santé et services sociaux (INESSS) recognising the urgency and need for a treatment for patients with SMA and...
Biogen salue la déci
Biogen salue la décision du Québec de rembourser SPINRAZAMC (nusinersen) pour une vaste population de patients atteints d’amyotrophie spinale (AS)
December 20, 2018 12:19 ET | Biogen Canada
MISSISSAUGA, Ontario, 20 déc. 2018 (GLOBE NEWSWIRE) -- Cette décision découle de la recommandation positive de l’Institut national d’excellence en santé et services sociaux (INESSS) qui...